GFM
XERS icon

GF Fund Management’s Xeris Biopharma Holdings XERS Stock Holding History

GF Fund Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.8K Sell
3,512
-198
-5% -$1.26K ﹤0.01% 451
2026
Q1 		$21.5K Buy
3,710
+450
+14% +$2.98K ﹤0.01% 494
2025
Q4 		$25.6K Sell
3,260
-214
-6% -$1.68K ﹤0.01% 480
2025
Q3 		$28.3K Sell
3,474
-343
-9% -$2.28K ﹤0.01% 449
2025
Q2 		$17.8K Hold
3,817
– – ﹤0.01% 512
2025
Q1 		$21K Buy
3,817
+687
+22% +$2.77K ﹤0.01% 499
2024
Q4 		$10.6K Buy
+3,130
New +$10.1K ﹤0.01% 538

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

GF Fund Management's XERS Position: Q2 2026 in Review

GF Fund Management reduced its Xeris Biopharma Holdings (XERS) stake by 5.3% in Q2 2026, selling an estimated $1.26K and leaving 3,512 shares worth $27.8K. The position accounts for ﹤0.01% of the portfolio, ranked #451.

GF Fund Management first reported a position in XERS in Q4 2024 and has held it in 7 quarters since. The position peaked at $28.3K in Q3 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • GF Fund Management held 3,512 shares of Xeris Biopharma Holdings worth $27.8K as of Q2 2026.
  • GF Fund Management sold 198 Xeris Biopharma Holdings shares in Q2 2026, an estimated $1.26K.
  • Xeris Biopharma Holdings made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #451 holding.
  • GF Fund Management first reported a position in Xeris Biopharma Holdings in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Xeris Biopharma Holdings position peaked at $28.3K in Q3 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.